UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of December 2023
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-799-6183
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On December 4, 2023, NeuroSense Therapeutics Ltd. (the “Company”) issued a press release announcing that it will report Phase 2b ALS topline primary safety and tolerability & secondary clinical efficacy endpoints on December 5, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.
On December 5, 2023, the Company issued a press release announcing that its Phase 2b ALS trial achieves primary safety and tolerability & secondary clinical efficacy endpoints. A copy of the press release is furnished herewith as Exhibit 99.2.
This Report on Form 6-K (other than the three paragraphs immediately preceding “About ALS” in Exhibit 99.2) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-262480) and Form F-3 (File No. 333-269306), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | NeuroSense Therapeutics Ltd. |
| | | |
| Date: December 5, 2023 | By: | /s/ Alon Ben-Noon |
| | | Alon Ben-Noon |
| | | Chief Executive Officer |
2
